The patent “Use of arylalkanolamines as sigma-1 receptor antagonists” (EP 3 113 768 B1) of the MedChemLab has been selected for the event BioVaria.
BioVaria targets technology scouts, business developers and investors highlighting commercially attractive licensing opportunities and promising startups from across Europe.
The Advisory Board selected the technology Treatment of neuropathic pain (Simona Collina, Daniela Rossi, Annamaria Marra, Marco Peviani, Daniela Curti) for the oral presentation